Other lipid agents × lipids

SynthesisThe Cochrane database of systematic reviews2017

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Amand F Schmidt et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 67,237 people · 2017

Randomised comparison

Lowered lipids

−14%−20% to −8%

Bigger than 3 in 10 on the map

As reported

OR 0.86, 95% CI 0.80–0.92

Randomised comparison

Raised adverse events & safety

+8%+4% to +12%

Bigger than 3 in 10 for adverse events & safety

As reported

OR 1.08, 95% CI 1.04–1.12

Range includes no effect

No clear effect on deaths

+2%−9% to +14%

Bigger than 1 in 10 for all-cause mortality

As reported

OR 1.02, 95% CI 0.91–1.14 · the paper's word: All-cause mortality

Three numbers in the abstract

the abstract, start to end

(RD) of 0.91% (odds ratio (OR) of 0.86, 95% CI 0.80 to 0.92; eight

or no effect on mortality (RD 0.03%, OR 1.02, 95% CI 0.91 to 1.14; 12

risk of any adverse events (RD 1.54%, OR 1.08, 95% CI 1.04 to 1.12; 13

← favours treatmentfavours comparator →
could be chance
Lipids
OR 0.860.80–0.92
All-cause mortality
OR 1.020.91–1.14
Adverse events & safety
OR 1.081.04–1.12
PCSK9 inhibitorsOther lipid agentsLipidsAll-cause mortalityAdverse events & safety

PCSK9 inhibitors × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted

PCSK9 inhibitors × all-cause mortalityhelps?replicated

unlikelylikely
1.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

60 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28453187